Bill Cance

Company: GRAIL

Job title: Distinguished Scientist, Medical Affairs

Seminars:

Beyond Genotyping & Tissue: Leveraging a Liquid Biopsy, Methylation-Based Platform Across the Cancer Care Continuum 9:00 am

GRAIL’s methylation technology overview and clinical studies Overview of Tumor Methylation Fraction (TMeF) for molecular response, risk stratification, prognosis/prediction and MRD Application focus: The use of GRAIL’s methylation technology in early-stage NSCLC prognosis and hematological cancer Read more

day: Day Two